Alterity Therapeutics Ltd.ASX: ATH

Phase 2 DMC Recommends Continuing Clinical Trial as Planned

Feb 6, 2024 at 8:30 AM UTC · Issued by Alterity Therapeutics Ltd.

Alterity Therapeutics Ltd has released a press release.

View Attachment